KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to $125.0 million.

  • Moderna's Share-based Compensation rose 1160.71% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $474.0 million, marking a year-over-year increase of 1732.67%. This contributed to the annual value of $429.0 million for FY2024, which is 4065.57% up from last year.
  • According to the latest figures from Q3 2025, Moderna's Share-based Compensation is $125.0 million, which was up 1160.71% from $130.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Share-based Compensation registered a high of $130.0 million during Q2 2025, and its lowest value of $30.0 million during Q1 2021.
  • Over the past 5 years, Moderna's median Share-based Compensation value was $75.0 million (recorded in 2023), while the average stood at $77.5 million.
  • Per our database at Business Quant, Moderna's Share-based Compensation surged by 8181.82% in 2021 and then soared by 1000.0% in 2023.
  • Moderna's Share-based Compensation (Quarter) stood at $37.0 million in 2021, then skyrocketed by 67.57% to $62.0 million in 2022, then increased by 27.42% to $79.0 million in 2023, then skyrocketed by 31.65% to $104.0 million in 2024, then increased by 20.19% to $125.0 million in 2025.
  • Its Share-based Compensation stands at $125.0 million for Q3 2025, versus $130.0 million for Q2 2025 and $115.0 million for Q1 2025.